Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab -Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Purpose Since the introduction of nab-paclitaxel plus gemcitabine (nab-P+GEM) as first-line (1L) treatment for metastatic pancreatic adenocarcinoma (mPDAC), optimal second-line (2L) chemotherapy after progression is unclear. We assessed clinical outcomes of 2L chemotherapy for disease that progressed on 1L nab-P+GEM.